Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC). However, acquired resistance to EGFR-TKI treatment remains a clinical challenge. In recent years, emerging research investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Weiwei, Yao, Chengyun, Pan, Qin, Zhang, Zhi, Ye, Jinjun, Shen, Bo, Zhou, Guoren, Fang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995697/
https://www.ncbi.nlm.nih.gov/pubmed/36910653
http://dx.doi.org/10.3389/fonc.2023.1120278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995697/
https://www.ncbi.nlm.nih.gov/pubmed/36910653
http://dx.doi.org/10.3389/fonc.2023.1120278

Ejemplares similares